Patrick Mauro Investment Advisor INC. Acquires New Position in Bristol Myers Squibb Company $BMY

Key Points

• Patrick Mauro Investment Advisor acquired 47,612 shares of Bristol Myers Squibb worth approximately $2.74 million, representing about 1.4% of its portfolio. Other institutional investors also initiated positions, with institutions and hedge funds collectively owning 76.41% of BMY.
• Bristol Myers Squibb reported quarterly EPS of $2.04, beating estimates of $1.60, while revenue reached $12.97 billion and rose 5.7% year over year. The company reaffirmed fiscal 2026 EPS guidance of $6.75–$7.00.
• BMY shares recently traded at $67.59, near their 52-week high, and the company maintains a quarterly dividend of $0.63, equivalent to a 3.7% annualized yield. Analysts’ consensus rating is “Moderate Buy”, with an average price target of $66.06.

Patrick Mauro Investment Advisor INC. acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 47,612 shares of the biopharmaceutical company's stock, valued at approximately $2,743,000. Bristol Myers Squibb comprises about 1.4% of Patrick Mauro Investment Advisor INC.'s portfolio, making the stock its 26th biggest position.

A number of other institutional investors have also recently bought and sold shares of BMY. Chancellor Financial Group WB LP acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at $334,000. Great Lakes Advisors LLC acquired a new stake in shares of Bristol Myers Squibb during the second quarter worth $11,073,000. Comprehensive Financial Planning Inc. PA bought a new stake in Bristol Myers Squibb in the second quarter valued at about $37,000. Avaii Wealth Management LLC bought a new stake in Bristol Myers Squibb in the second quarter valued at about $984,000. Finally, Compass Wealth Management LLC acquired a new position in Bristol Myers Squibb in the second quarter valued at about $325,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Trading Up 2.3%

BMY stock opened at $67.59 on Thursday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The company's 50-day simple moving average is $60.18 and its 200 day simple moving average is $59.24. The company has a market capitalization of $138.06 billion, a PE ratio of 14.89, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to analysts' expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm's revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.7%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 55.51%.

Analysts Set New Price Targets

BMY has been the topic of several recent analyst reports. Royal Bank Of Canada lifted their price objective on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a "sector perform" rating in a research note on Friday, July 31st. Weiss Ratings upgraded Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday. Wells Fargo & Company set a $65.00 price target on shares of Bristol Myers Squibb and gave the stock an "equal weight" rating in a research report on Friday, July 31st. BMO Capital Markets reissued a "market perform" rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Finally, Roth Capital started coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a "buy" rating and a $75.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of "Moderate Buy" and a consensus price target of $66.06.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source